Cardiomyopathy

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…

What is this plain language summary about? This summary presents the results from an ongoing, long-term extension studyexternal link, opens in a new tab that…

Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of…

Cardiac amyloidosis is a heterogeneous group of diseases characterized by extracellular deposition of amyloid fibrils in many different organs finally resulting in…

For the first time, we report of a Swedish family of five individuals with a TTR Glu54Leu (p. Glu74Leu) mutation in the transthyretin gene. This mutation has been…

The heart and the kidneys are the most commonly involved organs in systemic amyloidosis. Cardiac involvement is associated with an increased morbidity, treatment…

Amyloid cardiomyopathy should be suspected in any patient who presents with heart failure and preserved ejection fraction. In patients with echocardiographic…

Introduction: Cardiac amyloidosis is the most common cause of infiltrative cardiomyopathy and is associated with a poor prognosis. Transthyretin cardiac amyloidosis…

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL(R) (tafamidis meglumine) and VYNDAMAX(tm) (tafamidis) for…

Ronglih Liao is Co-Director of the Stanford Amyloid Center and Professor of Medicine at Stanford University School of Medicine. She is also a visiting Professor of…